446 related articles for article (PubMed ID: 29067652)
1. An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy.
Mah JK
Methods Mol Biol; 2018; 1687():3-17. PubMed ID: 29067652
[TBL] [Abstract][Full Text] [Related]
2. Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies.
Sheikh O; Yokota T
Expert Opin Investig Drugs; 2021 Feb; 30(2):167-176. PubMed ID: 33393390
[TBL] [Abstract][Full Text] [Related]
3. Emerging genetic therapies to treat Duchenne muscular dystrophy.
Nelson SF; Crosbie RH; Miceli MC; Spencer MJ
Curr Opin Neurol; 2009 Oct; 22(5):532-8. PubMed ID: 19745732
[TBL] [Abstract][Full Text] [Related]
4. [Mutation-specific treatments for Duchenne muscular dystrophy].
Matsuo M; Takeshima Y
Brain Nerve; 2009 Aug; 61(8):915-22. PubMed ID: 19697880
[TBL] [Abstract][Full Text] [Related]
5. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
Cai A; Kong X
Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
[TBL] [Abstract][Full Text] [Related]
6. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
7. PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment.
Negishi Y; Ishii Y; Nirasawa K; Sasaki E; Endo-Takahashi Y; Suzuki R; Maruyama K
Methods Mol Biol; 2018; 1687():185-192. PubMed ID: 29067664
[TBL] [Abstract][Full Text] [Related]
8. [Frontline studies on Duchenne muscular dystrophy treatment].
Matsuo M
No To Hattatsu; 2009 Mar; 41(2):92-5. PubMed ID: 19517771
[TBL] [Abstract][Full Text] [Related]
9. Exon skipping therapy for Duchenne muscular dystrophy.
Kole R; Krieg AM
Adv Drug Deliv Rev; 2015 Jun; 87():104-7. PubMed ID: 25980936
[TBL] [Abstract][Full Text] [Related]
10. Advances in the Treatment of Duchenne Muscular Dystrophy: New and Emerging Pharmacotherapies.
Reinig AM; Mirzaei S; Berlau DJ
Pharmacotherapy; 2017 Apr; 37(4):492-499. PubMed ID: 28152217
[TBL] [Abstract][Full Text] [Related]
11. Eteplirsen treatment for Duchenne muscular dystrophy: Exon skipping and dystrophin production.
Charleston JS; Schnell FJ; Dworzak J; Donoghue C; Lewis S; Chen L; Young GD; Milici AJ; Voss J; DeAlwis U; Wentworth B; Rodino-Klapac LR; Sahenk Z; Frank D; Mendell JR
Neurology; 2018 Jun; 90(24):e2146-e2154. PubMed ID: 29752304
[TBL] [Abstract][Full Text] [Related]
12. Mutation spectrum analysis of Duchenne/Becker muscular dystrophy in 68 families in Kuwait: The era of personalized medicine.
Mohammed F; Elshafey A; Al-Balool H; Alaboud H; Al Ben Ali M; Baqer A; Bastaki L
PLoS One; 2018; 13(5):e0197205. PubMed ID: 29847600
[TBL] [Abstract][Full Text] [Related]
13. Restoring dystrophin expression in duchenne muscular dystrophy muscle progress in exon skipping and stop codon read through.
Hoffman EP; Bronson A; Levin AA; Takeda S; Yokota T; Baudy AR; Connor EM
Am J Pathol; 2011 Jul; 179(1):12-22. PubMed ID: 21703390
[TBL] [Abstract][Full Text] [Related]
14. Exon-skipping therapy for Duchenne muscular dystrophy.
Nakamura A; Takeda S
Neuropathology; 2009 Aug; 29(4):494-501. PubMed ID: 19486303
[TBL] [Abstract][Full Text] [Related]
15. A novel canine model for Duchenne muscular dystrophy (DMD): single nucleotide deletion in DMD gene exon 20.
Mata López S; Hammond JJ; Rigsby MB; Balog-Alvarez CJ; Kornegay JN; Nghiem PP
Skelet Muscle; 2018 May; 8(1):16. PubMed ID: 29843823
[TBL] [Abstract][Full Text] [Related]
16. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
Jarmin S; Kymalainen H; Popplewell L; Dickson G
Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
[TBL] [Abstract][Full Text] [Related]
17. Comparison of mutation profiles in the Duchenne muscular dystrophy gene among populations: implications for potential molecular therapies.
López-Hernández LB; Gómez-Díaz B; Luna-Angulo AB; Anaya-Segura M; Bunyan DJ; Zúñiga-Guzman C; Escobar-Cedillo RE; Roque-Ramírez B; Ruano-Calderón LA; Rangel-Villalobos H; López-Hernández JA; Estrada-Mena FJ; García S; Coral-Vázquez RM
Int J Mol Sci; 2015 Mar; 16(3):5334-46. PubMed ID: 25761239
[TBL] [Abstract][Full Text] [Related]
18. Systemic Delivery of Morpholinos to Skip Multiple Exons in a Dog Model of Duchenne Muscular Dystrophy.
Maruyama R; Echigoya Y; Caluseriu O; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2017; 1565():201-213. PubMed ID: 28364245
[TBL] [Abstract][Full Text] [Related]
19. Duchenne muscular dystrophy: an updated review of common available therapies.
Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic developments for Duchenne muscular dystrophy.
Verhaart IEC; Aartsma-Rus A
Nat Rev Neurol; 2019 Jul; 15(7):373-386. PubMed ID: 31147635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
